PMID- 26928259
OWN - NLM
STAT- MEDLINE
DCOM- 20171109
LR  - 20231112
IS  - 1745-5065 (Electronic)
IS  - 1745-5057 (Print)
IS  - 1745-5057 (Linking)
VI  - 12
IP  - 3
DP  - 2016 Jun
TI  - Benefits/risks of sodium-glucose co-transporter 2 inhibitor canagliflozin in 
      women for the treatment of Type 2 diabetes.
PG  - 379-88
LID - 10.2217/whe-2016-0001 [doi]
AB  - Sodium-glucose co-transporter 2 (SGLT2) inhibitors, such as canagliflozin, are 
      used in patients with Type 2 diabetes mellitus (T2DM). In clinical studies, 
      canagliflozin significantly reduced A1C, bodyweight and blood pressure, and was 
      generally well tolerated with no increased risk of hypoglycemia. Most common 
      adverse effects observed were genital mycotic infections and urinary tract 
      infections, and increased urination. Approximately 10% of women treated with 
      canagliflozin experienced a genital mycotic infection compared with 3% treated 
      with placebo; those with a prior history were at greater risk. Approximately 9% 
      of women treated with canagliflozin reported a urinary tract infection compared 
      with 7% treated with placebo. Most adverse events were considered mild to 
      moderate in intensity and responded to standard therapy. Treatment with 
      canagliflozin was effective and generally well tolerated in both women (and men) 
      with T2DM.
FAU - Kushner, Pamela
AU  - Kushner P
AD  - University of California, Irvine, CA, USA.
AD  - Kushner Wellness Center, 3745 Long Beach Blvd, Suite 100, Long Beach, CA 90807, 
      USA.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20160229
PL  - United States
TA  - Womens Health (Lond)
JT  - Women's health (London, England)
JID - 101271249
RN  - 0 (Hypoglycemic Agents)
RN  - 0SAC974Z85 (Canagliflozin)
SB  - IM
MH  - Canagliflozin/administration & dosage/*adverse effects
MH  - Candidiasis, Vulvovaginal/chemically induced
MH  - Diabetes Mellitus, Type 2/*drug therapy
MH  - Female
MH  - Genital Diseases, Female/chemically induced
MH  - Humans
MH  - Hypoglycemic Agents/administration & dosage/*adverse effects
MH  - Urinary Tract Infections/chemically induced
PMC - PMC5384506
OTO - NOTNLM
OT  - SGLT2
OT  - T2DM
OT  - canagliflozin
OT  - efficacy
OT  - safety
OT  - women's health
EDAT- 2016/03/02 06:00
MHDA- 2017/11/10 06:00
PMCR- 2017/06/01
CRDT- 2016/03/02 06:00
PHST- 2016/03/02 06:00 [entrez]
PHST- 2016/03/02 06:00 [pubmed]
PHST- 2017/11/10 06:00 [medline]
PHST- 2017/06/01 00:00 [pmc-release]
AID - 10.2217_whe-2016-0001 [pii]
AID - 10.2217/whe-2016-0001 [doi]
PST - ppublish
SO  - Womens Health (Lond). 2016 Jun;12(3):379-88. doi: 10.2217/whe-2016-0001. Epub 
      2016 Feb 29.